gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Progesterone receptor

progesterone receptor, PgR
This gene encodes a member of the steroid receptor superfamily. The encoded protein mediates the physiological effects of progesterone, which plays a central role in reproductive events associated with the establishment and maintenance of pregnancy. This gene uses two distinct promotors and translation start sites in the first exon to produce two isoforms, A and B. The two isoforms are identical except for the additional 165 amino acids found in the N-terminus of isoform B and mediate their own response genes and physiologic effects with little overlap. [provided by RefSeq, Jan 2011] (from NCBI)
Top mentioned proteins: erbB-2, HAD, AGE, CAN, iMpact
Papers using progesterone receptor antibodies
Estrogen receptor-alpha (ER-alpha) suppresses expression of its variant ER-alpha 36
Wang Zhao-Yi et al., In Oncogene, 2008
... ER-α66, HER2/Neu, and progesterone receptor antibodies were obtained from Ventana Medical Systems, Inc ...
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH
Domagala Wenancjusz et al., In Virchows Archiv, 2008
... Cruz, CA), anti-estrogen receptor (clone 1D5, dilution 1:50; Dako, Glostrup, Denmark), and anti-progesterone receptor (clone PgR 636, dilution 1:50; Dako).
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Richardson Andrea L et al., In Breast Cancer Research : BCR, 2008
... were re-cut and sections were immunostained for ER (SP1 antibody, Neomarkers, Fremont, CA, USA), PR (PgR 636 antibody, Dako, Carpinteria, CA, USA) and ...
Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer
Schuler Linda A et al., In Breast Cancer Research : BCR, 2003
... (MAS-250) from Accurate Scientific (Westbury, NY, USA), proliferating cell nuclear antigen (PCNA; PC 10) and progesterone receptor (PR; A0098) from DAKO Cytomation (Carpinteria, CA, USA), ...
Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis
Ashankyty Ibraheem M. et al., In Pathology Research International, 2002
... Dako, Denmark), HER-2/neu (titer 1 : 50, Dako, Denmark), ER (clone 1D5, Dako, Denmark), and PR (clone PgR 636, Dako, Denmark), was performed by ...
more suppliers
Papers on progesterone receptor
Triple-negative breast cancer: advancements in characterization and treatment approach.
Mead et al., Santa Monica, United States. In Curr Opin Obstet Gynecol, Feb 2016
PURPOSE OF REVIEW: Triple-negative breast cancer (TNBC) comprises 15-20% of all breast cancer and is defined by the lack of estrogen and progesterone receptor expression and absence of human epidermal growth factor receptor 2 amplification.
Prognostic impact of neoadjuvant aglepristone treatment in clinicopathological parameters of progesterone receptor-positive canine mammary carcinomas.
Martín de Las Mulas et al., Córdoba, Spain. In Vet Comp Oncol, Feb 2016
UNASSIGNED: Neoadjuvant treatment of canine mammary carcinomas with the progesterone receptor (PR) antagonist aglepristone has a PR expression-related inhibiting effect on proliferation index (PI).
Differences in progesterone concentrations and mRNA expressions of progesterone receptors in bovine endometrial tissue between the uterine horns ipsilateral and contralateral to the corpus luteum.
Matsui et al., Gifu, Japan. In J Vet Med Sci, Feb 2016
The aim of the present study was to determine the endometrial tissue P4 concentrations and nuclear progesterone receptor (PGR), progesterone receptor membrane component 1 (PGRMC1) and PGRMC2 mRNA expressions in the cranial and middle part of the uterine horns during the luteal phase.
SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury.
Wang et al., Shanghai, China. In Oncol Rep, Feb 2016
UNASSIGNED: Triple-negative breast cancer (TNBC) is a special subtype of breast cancer, which is characterized by the negative form of estrogen receptor (ER), progesterone receptor (PR) and human epithelial growth factor receptor 2 (HER2).
Quantitative phosphoproteomics reveals genistein as a modulator of cell cycle and DNA damage response pathways in triple-negative breast cancer cells.
Wang et al., Beijing, China. In Int J Oncol, Feb 2016
UNASSIGNED: Around one sixth of breast cancer cases are classified as triple-negative breast cancer (TNBC), named after the absence of the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2); however, patients with TNBC suffer from poor clinical outcome and shortage of targeted therapy.
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
SELECT BC study group et al., Ōsaka, Japan. In Lancet Oncol, Jan 2016
Randomisation was done centrally with the minimisation method, with stratification by institution, liver metastasis, oestrogen and progesterone receptor status, previous treatment with taxanes or oral fluorouracil, and time from surgery to recurrence.
Biomarker assessment and molecular testing for prognostication in breast cancer.
Dabbs et al., Ottawa, Canada. In Histopathology, Jan 2016
Oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) define prognosis and identify tumours for targeted therapy, and remain the sole established single-molecule biomarkers defining the minimum breast cancer pathology data set.
Medical management of heavy menstrual bleeding.
Critchley et al., Edinburgh, United Kingdom. In Womens Health (lond Engl), Jan 2016
In addition, we describe the more novel option of selective progesterone receptor modulators and their current benefits and limitations.
Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
Lannin et al., New Haven, United States. In J Clin Oncol, Jan 2016
No differences in response rate for estrogen receptor (ER)/progesterone receptor (PR)-positive tumors were found, but compared with white women, black but not Hispanic or Asian women had a lower rate of pCR for ER/PR-negative, HER2-positive (43% v 54%, P = 0.001) and triple-negative tumors (37% v 43%, P < 0.001).
Metastatic gastric carcinoma from breast cancer mimicking primary linitis plastica: A case report.
Saito et al., Toyama, Japan. In Oncol Lett, Dec 2015
Immunohistochemistry revealed that the biopsied specimens of the gastric and lung tumors were positive for estrogen receptor (ER), progesterone receptor (PgR) and negative for human epithelial growth factor receptor-2 (HER2).
Ulipristal acetate for uterine fibroid-related symptoms.
Koskas et al., Paris, France. In Drugs Today (barc), Nov 2015
Ulipristal acetate (UPA) is an orally active synthetic selective progesterone receptor modulator (SPRM) characterized by a tissue-specific progesterone antagonist effect that reduces the proliferation of leiomyoma cells and induces apoptosis.
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
Gray et al., In Lancet, Nov 2015
RRs differed little by age, body-mass index, stage, grade, progesterone receptor status, or HER2 status.
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
Blanpain et al., Brussels, Belgium. In Nature, Oct 2015
Surprisingly, oncogenic Pik3ca(H1047R) mutant expression at physiological levels in basal cells using keratin (K)5-CreER(T2) mice induced the formation of luminal oestrogen receptor (ER)-positive/progesterone receptor (PR)-positive tumours, while its expression in luminal cells using K8-CReER(T2) mice gave rise to luminal ER(+)PR(+) tumours or basal-like ER(-)PR(-) tumours.
The role of BUB and CDC proteins in low-grade breast cancers.
Ellis et al., Nottingham, United Kingdom. In Lancet, Mar 2015
BUB1 and BUB3 expression was positively correlated with oestrogen and progesterone receptor expression whereas BUB1B was negatively correlated (p=0·01).
Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor.
Miyamoto et al., Baltimore, United States. In Dis Markers, 2014
These receptors include androgen receptor, estrogen receptors, glucocorticoid receptor, progesterone receptor, vitamin D receptor, retinoid receptors, peroxisome proliferator-activated receptors, and others including orphan receptors.
Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.
Garcia et al., Seattle, United States. In Am J Obstet Gynecol, 2012
Among women with atypical hyperplasia (but not complex hyperplasia) on progetin therapy, high progesterone receptor expression was associated with decreased risk of disease persistence/progression.
X-ray structures of progesterone receptor ligand binding domain in its agonist state reveal differing mechanisms for mixed profiles of 11β-substituted steroids.
de Vlieg et al., Oss, Netherlands. In J Biol Chem, 2012
X-ray structures of progesterone receptor ligand binding domain in its agonist state reveal differing mechanisms for mixed profiles of 11beta-substituted steroids.
Caveolin-1 interferes cell growth of lung cancer NCI-H446 cell through the interactions with phospho-ERK1/2, estrogen receptor and progestin receptor.
Lin et al., Dalian, China. In Biomed Pharmacother, 2012
CAV-1 affected cell growth of lung cancer NCI-H446 cell through the interactions with p-ERK1/2, estrogen receptor and progestin receptor
Hormone receptors expression in phyllodes tumors of the breast.
Yoon et al., Kwangju, South Korea. In Anal Quant Cytol Histol, 2012
The epithelial component demonstrated the expression for ER-alpha (45.6%, 36 of 79), ER-beta (37.2%, 29 of 78), PR (91.1%, 72 of 79), and AR (10.1%, 8 of 79).
Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes.
Graham et al., Sydney, Australia. In Plos One, 2011
The study presents the relationship between progesterone receptor genomic interaction and transcriptional response in breast cancer cells and immortalized normal breast cells.
More papers using progesterone receptor antibodies
EGFR related peptides and their cognate receptors in breast cancer
Thomas Shaji et al., In International Journal of Breast Cancer, 2000
... Immunohistochemistry for progesterone receptor (Diagnostic biosystems PR (hPRa2 + hPRa3 clone), ...
share on facebooktweetadd +1mail to friends